HCW Biologics Inc. (NASDAQ:HCWB) Financings
Financings
| Raise | Date |
|---|---|
| Debt financing Closed: US$3M raised Use of proceeds: Fund clinical and operating activities to complete the Phase 1 study of HCW9302 in alopecia areata and establish the Recommended Phase 2 Dose | Nov 5, 2026 |
| Private placement of units (pre-funded warrants with rights to common warrants) Announced: US$1.5M · US$1.6599 a unit · Warrants at US$1.66 for 66 months · Maxim Group LLC Dealers: Maxim Group LLC (lead) Use of proceeds: Continue HCW9302 clinical trials, advance IND-enabling studies for HCW11-018b and HCW11-040, and general corporate purposes | Sep 24, 2026 |
| Private placement of units (common stock or pre-funded warrants, with common warrants) Announced: US$1.6M · US$2.585 a unit · Warrants at US$2.585 for 66 months Buyers: Hing C. Wong, Ph.D.; Scott Garrett; Lee Flowers Insiders: CEO Hing C. Wong, Chairman Scott Garrett and SVP Lee Flowers participated on the same terms Use of proceeds: Continue HCW9302 clinical trials, advance IND-enabling studies for HCW11-018b and HCW11-040, and general corporate purposes | Jul 29, 2026 |
| Public offering of units (one share of common stock or pre-funded warrant and one warrant) Announced: about US$1.5M · US$0.6055 a unit · 1 warrant at US$0.6055 for 60 months · Maxim Group LLC Dealers: Maxim Group LLC (lead) Use of proceeds: Preclinical and clinical development, including HCW9302 clinical trials, and general corporate purposes | Feb 18, 2026 |
| Warrant exercise of common stock upon exercise of outstanding warrants Announced: about US$4M · US$2.66 a share · ½ warrant at US$2.41 for 66 months · Maxim Group LLC Dealers: Maxim Group LLC | Nov 19, 2025 |
| Public offering of units (one share of common stock or pre-funded warrant and two warrants) Closed: US$5M raised · US$7.45 a unit · Warrants at US$7.45 for 60 months · Maxim Group LLC Dealers: Maxim Group LLC (lead) Use of proceeds: Open clinical sites for the Phase 1 trial of HCW9302 in an autoimmune disorder | May 15, 2025 |